
Pepticom’s AI Discovered 53 Novel Immune-Mmodulators
Pepticom was honored with an image from their article on this December’s Journal of Immunology. The image is taken from Pepticom’s latest article “Computationally Designed Bispecific

Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game!
While current immunotherapies offer promise to previously untreatable cancers, they only work in a small percentage of patients with certain types of cancer. Scientists have

Enlivex Therapeutics merged into NASDAQ-based Co-Bioblast Pharma Ltd, of Dahlia Meggido
Bioblast Pharma Ltd. (Nasdaq:ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the

Hadasit & IBM set up digital health accelerator at Hadassah Ein Kerem, Jerusalem
Hadassah Medical Center in Jerusalem and IBM Israel have announced the establishment of a special accelerator for startups in which the startups can develop advanced

Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update
Completed enrollment in pivotal Phase 3 ACCORDANCE trial is on track for topline data in mid-2019 JERUSALEM, Nov. 9, 2018 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the

Positive results in Entera Bio’s pharmacokinetic (PK) & pharmacodynamic (PD) study in patients with hypoparathyroidism
Entera Bio Ltd. (Nasdaq: ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in

The New Scientist Reports on Biondvax’s Universal Flu Vaccine
For decades, scientists have been trying to develop a universal vaccine that would protect people against seasonal flu for years, and also against pandemics, which

Anchiano Therapeutics files for $30-40m Nasdaq offering
Jerusalem based cancer treatment company Anchiano Therapeutics (TASE: ANCN), formerly BioCancell Therapeutics, has announced the publication of a confidential prospectus for an offering on Nasdaq. It is

Results of Zion Medical’s First Human Clinical Trial of HIV drug Gammora Offers Potential Cure
Zion Medical, an Israeli biotech company developing HIV and cancer treatments, has announced the results of the first clinical trial of HIV-drug Gammora, eliminating up